Goddard Glenn

Goddard Glenn serves as the Executive Vice President at Intellia Therapeutics, Inc., a company focused on developing transformative gene-editing therapies. His recent trading activity includes four disclosed transactions from January 3, 2024, to March 5, 2024, all related to Intellia Therapeutics (NTLA). Notably, Glenn's largest move was a grant/exercise valued at approximately $1.3 million, indicating significant insider activity during this period.